Abstract
the Brazilian Universal Health System (BUHS) enact several policies to reduce access barriers to biological medicines, favoring biosimilars. After seven years since the authorization of the first biosimilars, we investigated the major gaps that hinders a greater participation of these products in the market.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
